Schell, Michael J.

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study

Scott, J. G., Berglund, A., Schell, M. J., Mihaylov, I., Fulp, W. J., Yue, B., Welsh, E., Caudell, J. J., Ahmed, K., Strom, T. S., et al. (2017) · The Lancet Oncology

Breast Cancer Treatment StudiesAdvanced Radiotherapy Techniques

Cited by 474

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 248

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC

Schell, M. J., Yang, M., Teer, J. K., Lo, F. Y., Madan, A., Coppola, D., Monteiro, A. N. A., Nebozhyn, M. V., Yue, B., Loboda, A., et al. (2016) · Nature Communications

Genetic factors in colorectal cancerColorectal Cancer Treatments and Studies

Cited by 207

Influence of Mindfulness-Based Stress Reduction (MBSR) on Telomerase Activity in Women with Breast Cancer (BC)

Lengacher, C. A., Reich, R. R., Kip, K. E., Barta, M., Ramesar, S., Paterson, C. L., Moscoso, M. S., Carranza, I., Budhrani, P. H., Kim, S. J., et al. (2014) · Biological Research For Nursing

Mindfulness and Compassion InterventionsCancer survivorship and care

Cited by 169

Phase II Clinical Trial of Pasireotide Long-Acting Repeatable in Patients with Metastatic Neuroendocrine Tumors

Cives, M., Kunz, P. L., Morse, B., Coppola, D., Schell, M. J., Campos, T., Nguyen, P. T., Nandoskar, P., Khandelwal, V, & Strosberg, J. R. (2015) · Endocrine-Related Cancer

Neuroendocrine Tumor Research AdvancesPituitary Gland Disorders and Treatments

Cited by 96

A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome

Schell, M. J., Yang, M., Missiaglia, E., Delorenzi, M., Soneson, C., Yue, B., Nebozhyn, M. V., Loboda, A., Bloom, G., & Yeatman, T. J. (2016) · Clinical Cancer Research

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 42

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation

Davis, T. B., Yang, M., Schell, M. J., Wang, H., Ma, L., Pledger, W. J., & Yeatman, T. J. (2018) · Scientific Reports

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 27

Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

Omolo, B., Yang, M., Lo, F. Y., Schell, M. J., Austin, S., Howard, K., Madan, A., & Yeatman, T. J. (2016) · BMC Medical Genomics

Colorectal Cancer Treatments and StudiesGene expression and cancer classification

Cited by 25

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy

Yang, M., Davis, T. B., Pflieger, L., Nebozhyn, M. V., Loboda, A., Wang, H., Schell, M. J., Thota, R., Pledger, W. J., & Yeatman, T. J. (2022) · BMC Cancer

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 22